2-氨基-5-溴烟酸甲酯 | 50735-34-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-5-溴烟酸甲酯
• 中文别名: 2-氨基-5-溴吡啶-3-羧酸甲酯；2-氨基-5-溴-烟酸甲酯
• 英文名称: methyl 2-amino-5-bromonicotinate
• 英文别名: methyl 2-amino-5-bromopyridine-3-carboxylate；2-amino-5-bromonicotinic acid methyl ester
• CAS: 50735-34-7
• 化学式: C₇H₇BrN₂O₂
• 分子量: 231.049
• InChiKey: POWKBBOOIZBIRZ-UHFFFAOYSA-N

物化性质

• 熔点：
  143-146°C
• 沸点：
  275.2±35.0 °C(Predicted)
• 密度：
  1.662±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 2-amino-5-bromonicotinate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-amino-5-bromonicotinate
CAS number: 50735-34-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7BrN2O2
Molecular weight: 231

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴烟酸甲酯 在 盐酸 、 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 27.0h， 生成 methyl 2-amino-5-(1-(1-methylpiperidin-4-yl)pyrazol-4-yl)nicotinate
  参考文献：
  名称：

  Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers

  摘要：

  Starting from potent inhibitors of PI3K alpha having poor general kinase selectivity (e.g., 1 and 2), optimisation of this series led to the identification of 25, a potent inhibitor of PI3K alpha (wild type, E545K and H1047R mutations) and PI3K delta, selective versus PI3K beta and PI3K gamma, with excellent general kinase selectivity. Compound 25 displayed low metabolic turnover and suitable physical properties for oral administration. In vivo, compound 25 showed pharmacodynamic modulation of AKT phosphorylation and near complete inhibition of tumour growth (93% tumour growth inhibition) in a murine H1047R PI3K alpha mutated SKOV-3 xenograft tumour model after chronic oral administration at 25 mg/kg b.i.d. Compound 25, also known as AZD8835, is currently in phase I clinical trials. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.002
• 作为产物：
  描述：

  2-氨基烟酸 在 硫酸 、 溴 、 溶剂黄146 作用下， 反应 38.0h， 生成 2-氨基-5-溴烟酸甲酯
  参考文献：
  名称：

  DYRK1A抑制剂的多种杂环双酚化合物的合成及体外评价

  摘要：

  双特异性酪氨酸磷酸化相关激酶1A（DYRK1A）是一种双特异性蛋白激酶，可催化磷酸化和自身磷酸化。较高的DYRK1A表达与癌症有关，特别是与脑内存在的胶质母细胞瘤有关。我们在这里报告设计为新型DYRK1A抑制剂的新型杂环二酚衍生物的合成和生物学评估。根据DANDY铅的结构修饰，制备了这些杂环，如苯并咪唑，咪唑，萘啶，吡唑-吡啶，联吡啶和三唑并吡嗪，并测试了它们抑制DYRK1A的能力。这些衍生物均未显示出明显的DYRK1A抑制作用，但提供了有关7-氮杂吲哚部分重要性的有价值的知识。

  DOI：

  10.1016/j.bmc.2018.10.034

文献信息

• [EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019147782A1

  公开（公告）日：2019-08-01

  The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

  该公开涉及到公式I的化合物，这些化合物可用作激酶调节剂，包括RIPK1调节。该公开还提供了制备和使用这些化合物的方法，例如在涉及坏死或炎症以及其他适应症的治疗中使用。
• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS<br/>[FR] COMPOSÉS D'INDOLE SUBSTITUÉS PAR [1,2,4] TRIAZOLO [1,5-A] PYRIDINYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018005586A1

  公开（公告）日：2018-01-04

  Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  揭示了Formula (I)或其盐的化合物，其中R1、R2、R3、R4、R5、m、n和p在此处被定义。还揭示了使用这些化合物作为通过Toll样受体7、8或9信号传导的抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗炎症性和自身免疫性疾病方面是有用的。
• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20090233925A1

  公开（公告）日：2009-09-17

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] AMPK MODULATORS<br/>[FR] MODULATEURS DE L'AMPK
  申请人：MERCURY THERAPEUTICS INC

  公开号：WO2009100130A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II), which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.

  本发明涉及公式（I）或（II）的化合物和药用可接受的盐、酯和前药，这些化合物在治疗受试者的糖尿病、肥胖和癌症方面作为有效的AMPK调节剂。
• [EN] AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS<br/>[FR] AMINOTRIAZOLOPYRIDINES UTILISÉES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018148626A1

  公开（公告）日：2018-08-16

  Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

  具有化学式（I）（IX）的化合物，以及其对映体、非对映体、立体异构体、药学上可接受的盐和前药，可用作激酶调节剂，包括RIPK1调节。所有变量的定义如下：（I）、（II）、（III）、（IV）、（V）、（VI）、（VII）、（VIII）、（IX）。